Wedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change Downgrades

Jefferies Cuts PTC Therapeutics (PTCT) Target to $8March 1, 2016 9:13 AM RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%March 1, 2016 8:54 AM Cowen Downgrades PTC Therapeutics (PTCT) to Market PerformMarch 1, 2016 7:27 AM PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateFebruary 29, 2016 4:01 PM Germany Seeks PTC Therapeutics (PTCT) Translarna Discount - OppenheimerFebruary 29, 2016 9:32 AM PTC Therapeutics (PTCT) Offers Update on German Pricing and Reimbursement Process for TranslarnaFebruary 26, 2016 4:02 PM PTC Therapeutics Provides Update on German pricing and Reimbursement Process for Translarna™ (ataluren)February 26, 2016 4:01 PM PTC Therapeutics (PTCT) Shares Decline; German Reimbursement Arbitration Panel Said to Cut Price of Ataluren by 65%February 26, 2016 3:37 PM